Core Viewpoint - Easterly Government Properties (DEA) has shown a slight increase of 0.1% in share price over the past four weeks, closing at $20.92, with a potential upside of 35% based on Wall Street analysts' mean price target of $28.25 [1][11]. Price Targets and Analyst Estimates - The mean estimate for DEA comprises five short-term price targets with a standard deviation of $3.26, indicating variability among analysts. The lowest estimate suggests a 13.5% increase to $23.75, while the highest target predicts a 55.4% surge to $32.50 [2][9]. - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Market Sentiment - Analysts are optimistic about DEA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11][12]. - The Zacks Consensus Estimate for DEA has increased by 0.8% over the past month, reflecting a positive revision trend with no negative adjustments [12]. Zacks Rank and Investment Potential - DEA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside in the near term [13].

Shares of Intapp (INTA) have gained 7.3% over the past four weeks to close the last trading session at $56.31, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $71 indicates a potential upside of 26.1%.The mean estimate comprises eight short-term price targets with a standard deviation of $7.95. While the lowest estimate of $60 indicates a 6.6% increase from the current price lev ...

Core Viewpoint - Honest (HNST) shares have increased by 14.5% in the past four weeks, closing at $5.07, with a potential upside indicated by Wall Street analysts' mean price target of $7.14, suggesting a 40.8% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $0.85, where the lowest estimate is $5.50 (8.5% increase) and the highest is $8 (57.8% increase) [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about HNST's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has risen by 47.6% over the past month, with two estimates increasing and no negative revisions [12] - HNST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]

Shares of Kemper (KMPR) have gained 12.8% over the past four weeks to close the last trading session at $65.52, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $82.20 indicates a potential upside of 25.5%.The mean estimate comprises five short-term price targets with a standard deviation of $5.72. While the lowest estimate of $75 indicates a 14.5% increase from the current price ...

Group 1 - Mind Medicine (MindMed) Inc. (MNMD) closed at $6.45, with a 16.2% gain over the past four weeks, and a mean price target of $24.50 suggests a 279.8% upside potential [1] - The average of 10 short-term price targets ranges from a low of $16 to a high of $55, with a standard deviation of $12.13, indicating a potential increase of 148.1% to 752.7% from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 1.4% over the past month [11][12] Group 2 - MNMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a solid potential upside [13] - The consensus price target, while not entirely reliable, suggests a positive direction for price movement, supported by analysts' growing optimism regarding the company's earnings prospects [4][11]

Core Viewpoint - Centrus Energy Corp. (LEU) has shown a significant price increase of 46% over the past four weeks, with a mean price target of $148.33 indicating a potential upside of 56.6% from the current price of $94.71 [1] Price Targets and Analyst Consensus - The average price target for LEU includes six short-term estimates, ranging from a low of $69 to a high of $300, with a standard deviation of $79.84, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 27.2%, while the highest points to a potential upside of 216.8% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about LEU's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 9.9% increase in the Zacks Consensus Estimate over the past month [11][12] - The company currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - 10x Genomics (TXG) shares have increased by 14.7% recently, with a mean price target of $14.79 suggesting a potential upside of 55.9% from the current price of $9.49 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $3.79, indicating variability among analysts [2] - The lowest estimate of $11 indicates a 15.9% increase, while the highest estimate suggests a 174% surge to $26 [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about TXG's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 14.6%, with five estimates moving higher and no negative revisions [12] - TXG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Shares of Spyre Therapeutics (SYRE) have gained 14.7% over the past four weeks to close the last trading session at $14.93, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $53.50 indicates a potential upside of 258.3%.The mean estimate comprises 10 short-term price targets with a standard deviation of $16.36. While the lowest estimate of $21 indicates a 40.7% increase from the c ...

Group 1 - Dream Finders Homes Inc. (DFH) has surpassed resistance at the 50-day moving average, indicating a potential short-term bullish trend [1] - DFH has moved 8.6% higher over the last four weeks, suggesting it may be on the verge of another rally [2] - The company is currently rated as a Zacks Rank 2 (Buy), reflecting positive investor sentiment [2] Group 2 - There have been two positive earnings estimate revisions for DFH, with none being lowered for the current fiscal year, indicating strong earnings momentum [2] - The consensus earnings estimate for DFH has also increased, further strengthening the bullish outlook [2][3] - The combination of positive earnings revisions and key technical levels suggests that DFH could see more gains in the near future [3]

Core Viewpoint - Sezzle Inc. (SEZL) shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][3]. Earnings Estimate Revisions - The upward trend in earnings estimate revisions indicates growing analyst optimism regarding Sezzle's earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, Sezzle is projected to earn $0.56 per share, reflecting a 55.56% increase from the previous year [7]. - Over the last 30 days, the Zacks Consensus Estimate for Sezzle has risen by 39.13%, with two estimates moving higher and no negative revisions [7]. - For the full year, the earnings estimate is $3.24 per share, representing a 76.09% increase from the prior year [8]. - The consensus estimate for the current year has also seen positive revisions, with two estimates increasing and no negative changes [8]. Zacks Rank and Performance - Sezzle currently holds a Zacks Rank 1 (Strong Buy), indicating strong agreement among analysts in raising earnings estimates [9]. - The Zacks Rank system has a proven track record, with Zacks 1 Ranked stocks averaging a 25% annual return since 2008 [3]. - Stocks with Zacks Rank 1 and 2 significantly outperform the S&P 500, suggesting a favorable investment environment for Sezzle [9]. Stock Performance - Sezzle shares have increased by 125.6% over the past four weeks, indicating strong investor confidence in the company's earnings growth prospects [10].